会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明授权
    • 항 비만 펩타이드의 지속형 결합체
    • 抗肥胖肽的持久结合
    • KR101767570B1
    • 2017-08-14
    • KR1020100104385
    • 2010-10-26
    • 한미사이언스 주식회사
    • 박성희신령애임창기정성엽권세창
    • A61K47/48A61K47/36A61K38/22A61K38/26
    • 본발명은 GLP-1 수용체와글루카곤수용체에동시에작용하는항 비만펩타이드의지속형제형을위한결합체및 이의제조방법에관한것이다. 보다구체적으로, 항비만펩타이드, 비펩타이드성중합체및 면역글로블린 Fc 영역이공유결합에의해상호연결되어있으며, 특정아미노산잔기에대한부위선택적결합과특정아미노산및 아미노산잔기의변형에의해생체내 효력지속효과를보다획기적으로증가시킨항 비만펩타이드결합체및 이의제조방법에관한것이다. 본발명의결합체는생체내 활성이높게유지되고, 혈중반감기가현저히증가되어비만치료에유용하게사용될수 있다.
    • 本发明涉及一种共轭和该同时的GLP-1受体和胰高血糖素受体起作用的抗肥胖肽的连续型同胞的方法。 更具体地,抗肥胖肽,非肽聚合物和免疫球蛋白,和Fc区是通过共价键彼此连接,站点选择性结合和体内作用由特定氨基酸和氨基酸残基的修饰对特定氨基酸残基作用持久 更具体地说,涉及一种抗肥胖肽缀合物及其制备方法。 本发明的共轭物被保持在体内活性高,血清半衰期显着增加可以是在肥胖症的治疗是有用的。
    • 4. 发明公开
    • 대장균의 고농도 배양방법
    • 培养高密度脂蛋白的方法
    • KR1020130105433A
    • 2013-09-25
    • KR1020130025941
    • 2013-03-12
    • 한미사이언스 주식회사
    • 허용호오의림정성엽권세창
    • C12N1/21C12N15/70C12Q1/02
    • C12P21/00C12N1/20
    • PURPOSE: A method for high cell density culture of Escherichia coli (E. coli) is provided to increase the number of E. coli by promoting proliferation of transformed E. coli for producing a target recombinant protein in high cell density. CONSTITUTION: A method for high cell density culture of E. coli comprises the steps of: performing batch culture of E. coli using a medium for bacterial growth until the pH of the medium increases by 0.1 or higher; adding a primary injection medium when the pH of the medium increases by 0.1 or higher and performing fed-batch culture so as to increase E. coli production; and adding a secondary medium when the absorbance (OD 600) of the medium is 150 or higher and culturing E. coli with fed-batch culture. The E. coli is transformed to express recombinant proteins.
    • 目的:提供大肠杆菌(E.coli)高细胞密度培养的方法,通过促进转化大肠杆菌的增殖来增加大肠杆菌的数量,以产生高细胞密度的靶重组蛋白。 构成:用于大肠杆菌高细胞密度培养的方法包括以下步骤:使用用于细菌生长的培养基进行大肠杆菌的分批培养,直到培养基的pH增加0.1或更高; 当培养基的pH增加0.1或更高时,加入初级注射培养基,进行补料分批培养,以增加大肠杆菌生产; 并且当培养基的吸光度(OD 600)为150或更高时培养第二培养基并用补料分批培养培养大肠杆菌。 转化大肠杆菌表达重组蛋白。
    • 5. 发明公开
    • 면역글로불린 Fc 단편 유도체
    • IMMUNGLOBULIN FC FRAGMENT的衍生物
    • KR1020130078633A
    • 2013-07-10
    • KR1020110147683
    • 2011-12-30
    • 한미사이언스 주식회사
    • 오의림허용호황상연최인영정성엽권세창
    • C07K16/28C07K19/00A61K39/395
    • A61K47/48561A61K38/26A61K47/6849C07K16/00C07K16/283C07K2317/52C07K2317/92C07K2317/94C07K2319/00C07K2319/30
    • PURPOSE: An immunoglobulin Fc fragment derivative is provided to have extended in vivo half life by high binding affinity to neonatal Fc receptor (FcRn) and to manufacture a sustained formulation of a protein drug. CONSTITUTION: An immunoglobulin Fc fragment derivative has the modification of amino acid residues selected from a group consisting of 308F, 380S, 380A, 428L, 429K, 430S, 433K, and 434S (the numbering is based on EU index) in the constant region of a wild type immunoglobulin Fc fragment. The immunoglobulin Fc fragment derivative has enhanced binding affinity to FcRn. The modification of the amino acid residue is selected from a group consisting of 428L/434S, 433K/434S, 429K/433K, 428L/433K, 308F/380A, 307S/380S, and 380S/434S. A method for enhancing in vivo half life of a physiologically active polypeptide comprises the step of binding the immunoglobulin Fc fragment derivative with the physiologically active polypeptide through covalent bond by a non-peptidyl polymer.
    • 目的:提供免疫球蛋白Fc片段衍生物以通过对新生儿Fc受体(FcRn)的高结合亲和力延长体内半衰期,并制备蛋白质药物的持续制剂。 构成:免疫球蛋白Fc片段衍生物具有选自308F,380S,380A,428L,429K,430S,433K和434S(编号基于EU指数)的氨基酸残基在恒定区中的修饰 野生型免疫球蛋白Fc片段。 免疫球蛋白Fc片段衍生物具有增强的对FcRn的结合亲和力。 氨基酸残基的修饰选自428L / 434S,433K / 434S,429K / 433K,428L / 433K,308F / 380A,307S / 380S和380S / 434S。 提高生理活性多肽的体内半衰期的方法包括通过非肽基聚合物通过共价键将免疫球蛋白Fc片段衍生物与生理活性多肽结合的步骤。
    • 6. 发明公开
    • 옥신토모듈린과 면역글로불린 단편을 포함하는 결합체 및 그의 용도
    • 包含氧化色氨酸和免疫球蛋白片段的结合物及其用途
    • KR1020120139579A
    • 2012-12-27
    • KR1020120064110
    • 2012-06-15
    • 한미사이언스 주식회사
    • 정성엽김대진박성희우영은최인영권세창
    • C07K14/605C07K16/00A61K38/26A61K39/395
    • A61K47/6889A61K38/00A61K38/26A61K45/06A61K47/60A61K47/68A61K47/6801A61K47/6811C07K14/575C07K2319/30
    • PURPOSE: A protein conjugate containing oxyntomodulin and immunoglobulin Fc region and a pharmaceutical composition containing the same for preventing or treating obesity are provided to promote adipose decomposition and to safely and effectively treat obesity. CONSTITUTION: A conjugate contains oxyntomodulin and immunoglobulin Fc region which are conjugated by non-peptidal polymers. The oxyntomodulin has an amino acid sequence of sequence number 1. The oxyntomodulin is an oxyntomodulin derivative prepared by addition, deletion, or substitution of wild type oxyntomodulin. The both ends of the non-peptidal polymers are conjugated to an amine group or a thiol group of the immunoglobulin Fc region and oxyntomodulin. A pharmaceutical composition for preventing or treating obesity contains the conjugate. The pharmaceutical composition is administered solely or is combined with other pharmaceutical formulation for prevent or treating obesity.
    • 目的:提供含有胃泌酸调节蛋白和免疫球蛋白Fc区的蛋白质缀合物和含有其的用于预防或治疗肥胖症的药物组合物,以促进脂肪分解并安全有效地治疗肥胖症。 构成:缀合物含有由非肽性聚合物结合的胃泌酸调节蛋白和免疫球蛋白Fc区。 胃泌酸调节素具有序列号1的氨基酸序列。胃泌酸调节蛋白是通过野生型胃泌酸调节蛋白的添加,缺失或取代制备的胃泌酸调节蛋白衍生物。 非肽性聚合物的两端与免疫球蛋白Fc区的胺基或硫醇基缀合,并且与胃泌酸调节蛋白结合。 用于预防或治疗肥胖症的药物组合物含有缀合物。 药物组合物单独施用或与其它药物制剂组合以预防或治疗肥胖症。
    • 10. 发明公开
    • 인간 난포자극 호르몬의 대량 생산 방법
    • 人类激素刺激大鼠生产方法
    • KR1020110090604A
    • 2011-08-10
    • KR1020100010486
    • 2010-02-04
    • 한미사이언스 주식회사
    • 김창환홍성갑박성희김진선최인영권세창
    • C12N15/63C12N15/85C07K14/59C12N9/06
    • C12N15/63C07K14/59C12N9/003C12N15/85C12N2015/8518
    • PURPOSE: A method for producing a large amount of human follicle-stimulating hormone is provided to manufacture a therapeutic agent for infertility. CONSTITUTION: A method for producing a large amount of human follicle-stimulating hormone comprises: a step of transforming an animal cell line with an expression vector; and a step of culturing the animal cell line under the presence of DHFR inhibitor. The expression vector comprises: GC-rich repetitive sequence-deleted DHFR promoter and a gene encoding DHFR, which is operatively linked to the promoter; a promoter of CMV(cytomegalovirus) initial gene and a human follicle-stimulating hormone beta subunit gene which is operatively linked to the promoter; and a CMV initial gene promoter or RSV(Rous sarcoma virus) promoter, and the human follicle-stimulating hormone beta subunit gene which is operatively linked to the promoter.
    • 目的:提供一种产生大量人促卵泡激素的方法,用于制造不育症的治疗剂。 构成:产生大量人促卵泡激素的方法包括:用表达载体转化动物细胞系的步骤; 以及在DHFR抑制剂存在下培养动物细胞系的步骤。 表达载体包括:富含GC的重复序列缺失的DHFR启动子和编码DHFR的基因,其与启动子有效连接; CMV(巨细胞病毒)初始基因的启动子和与启动子有效连接的人卵泡刺激素β亚基基因; 和CMV初始基因启动子或RSV(Rous肉瘤病毒)启动子,以及与启动子有效连接的人卵泡刺激素β亚基基因。